Patents Assigned to Universitat Basel
-
Patent number: 11904051Abstract: A liposome vesicle comprising a membrane consisting of 1,3-diheptadecanamidopropan-2-yl(2-(trimethylammonio)ethyl)phosphate surrounding a volume comprising a pharmaceutical drug or contrast agent. The vesicle is mechanosensitive at body temperature and at physiologically or pathophysiologically relevant shear stress.Type: GrantFiled: January 31, 2019Date of Patent: February 20, 2024Assignees: Universität Basel, Universität FreiburgInventors: Bert Müller, Andreas Zumbühl, Thomas Pfohl, Dennis Müller, Frederik Neuhaus, Radu Tanasescu, Till Saxer, Marzia Buscema, Sofiya Matviykiv, Gabriela Gerganova
-
Patent number: 11896707Abstract: The present invention relates to the use of plant extracts from the genus Daphne for the cosmetic treatment of the skin and to cosmetic preparations which comprise extracts of Daphne giraldii and/or Daphne gnidium or other members of the genus Daphne containing daphnetoxin and/or other daphnane diterpenoids for skin treatment. The plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system.Type: GrantFiled: December 10, 2019Date of Patent: February 13, 2024Assignees: ETH Zurich, Universität BaselInventors: Michael Detmar, Epameinondas Gousopoulos, Olivier Potterat, Jihye Kim, Adriana Sliwa-Primorac, Antonia Elisabeth Schantl, Maria Teresa Faleschini, Matthias Hamburger
-
Patent number: 11878972Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; R1 and R2 are independently of each other (iii) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkType: GrantFiled: December 17, 2020Date of Patent: January 23, 2024Assignees: TORQUR AG, UNIVERSITÄT BASELInventors: Denise Rageot, Paul Hebeisen, Florent Beaufils, Doriano Fabbro, Petra Hillmann-Wüllner, Hoa Huu Phuc Nguyen, Wolfgang Löscher, Claudia Brandt, Alexander Markus Sele
-
Publication number: 20240010682Abstract: The present invention relates to a hemostatic elastin-like polypeptide comprising a glutamine embedded in a Q-block sequence and, optionally, a lysine embedded in a K-block sequence. Under physiological setting, the Q-block sequence and the K-block sequence are recognized by human transglutaminase factor XIIIa and crosslinked with fibrin networks. The present invention also relates to the medical use of the polypeptide, to a nucleic acid sequence encoding the polypeptide, to an expression vector comprising the nucleic acid sequence, and to a cell comprising the nucleic acid sequence or the expression vector.Type: ApplicationFiled: August 17, 2021Publication date: January 11, 2024Applicant: UNIVERSITÄT BASELInventors: Michael Adam NASH, Ivan UROSEV
-
Publication number: 20240002465Abstract: Described herein is a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.Type: ApplicationFiled: July 17, 2023Publication date: January 4, 2024Applicant: UNIVERSITÄT BASELInventors: Gennaro DE LIBERO, Marco LEPORE, Lucia MORI
-
Patent number: 11860071Abstract: Method for preparing a sample, wherein the sample is provided as a thin film on a support structure; the temperature of the support structure is adjusted to a value above the dew point temperature of the environment to decrease the film thickness, light is directed at the support structure, an intensity value of the transmitted light is measured, and the support structure is automatically inserted into a liquid cryogen dependent on the measured intensity value. The application further relates to a system comprising a support structure, a temperature-controlled stage for keeping the support structure at a pre-defined temperature, a transfer mechanism for moving the support structure into a container containing a liquid cryogen, a light source, a photodetector for measuring an intensity value of the transmitted light, and a control device for triggering the transfer mechanism dependent on the measured intensity value.Type: GrantFiled: October 17, 2017Date of Patent: January 2, 2024Assignee: UNIVERSITAT BASELInventors: Thomas Braun, Stefan Arnold, Henning Stahlberg
-
Patent number: 11807676Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.Type: GrantFiled: March 7, 2022Date of Patent: November 7, 2023Assignees: UNIVERSITÄT ZÜRICH, UNIVERSITÄT BASELInventors: Osiris Marroquin Belaunzaran, Christoph Renner
-
Publication number: 20230353350Abstract: The invention relates to a method for device-independent quantum key generation and distribution between a first and a second receiver, the method comprising the steps of: a) Generating an entangled information pair, comprising two entangled quantum moieties that have at least one quantum state entangled with each other, such as a polarization, b) Transmitting a first entangled quantum moiety of the two entangled quantum moieties to the first receiver (A) and a second entangled quantum moiety of the two entangled quantum moieties to the second receiver (B), and measuring the quantum states of the entangled moieties with a set of selected detection settings chosen randomly at each receiver c) In a modification step, assigning each measurement value b1 measured with a detection setting B1 a complementary value b 1 ? according to a noise-probability p, wherein the noise-probability p is larger than 0 and lower than 1, such that a modified plurality of measurement values b 1 ˜ is obtainedType: ApplicationFiled: May 12, 2021Publication date: November 2, 2023Applicants: ETH ZURICH, UNIVERSITÄT BASELInventors: Melvyn HO, Pavel SEKATSKI, Jean-Daniel BANCAL, Nicolas SANGOUARD, Ernest TAN, Renato RENNER
-
Publication number: 20230344201Abstract: The present invention relates to a single photon source, comprising: a microcavity arranged between a concave first minor and a semiconductor heterostructure forming a planar second minor, wherein the microcavity supports an optical mode, a quantum dot embedded in the semiconductor heterostructure and facing the first minor, and a laser light source configured to provide laser light in the microcavity to excite the quantum dot to emit single photons exiting the microcavity.Type: ApplicationFiled: July 15, 2021Publication date: October 26, 2023Applicant: UNIVERSITÄT BASELInventors: Richard J. WARBURTON, Alisa JAVADI, Daniel NAJER, Natasha TOMM
-
Patent number: 11702459Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.Type: GrantFiled: September 9, 2019Date of Patent: July 18, 2023Assignee: UNIVERSITÄT BASELInventors: Gennaro De Libero, Marco Lepore, Lucia Mori
-
Patent number: 11702663Abstract: The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of repeated domains of a heterologous protein or two or more domains of different heterologous proteins into eukaryotic cells.Type: GrantFiled: November 17, 2016Date of Patent: July 18, 2023Assignee: Universität BaselInventors: Simon Ittig, Marlise Amstutz, Christoph Kasper
-
Patent number: 11686720Abstract: The invention relates to a method for classifying a tissue sample obtained from mammary carcinoma. The method comprises determining a stiffness value for each of a plurality of points on said tissue sample, resulting in a stiffness distribution, and assigning said sample to a breast cancer subtype and nodal status based on said stiffness distribution.Type: GrantFiled: October 24, 2016Date of Patent: June 27, 2023Assignee: UNIVERSITAT BASELInventors: Marija Plodinec, Ellen Obermann, Philipp Oertle, Christian Räz
-
Patent number: 11662354Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.Type: GrantFiled: March 15, 2022Date of Patent: May 30, 2023Assignee: UNIVERSITÄT BASELInventors: Gilbert Koch, Sven Wellmann, Marc Pfister, Severin Kasser, Melanie Wilbaux
-
Patent number: 11656234Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.Type: GrantFiled: September 27, 2018Date of Patent: May 23, 2023Assignee: UNIVERSITÄT BASELInventors: Gilbert Koch, Sven Wellmann, Marc Pfister, Severin Kasser, Melanie Wilbaux
-
Patent number: 11617495Abstract: A medical endodevice for an intervention inside a human or animal body includes an elongated liaising structure having a distal end arrangeable inside a body of the human or animal being and a proximal end arrangeable outside the body while the distal end is inside the body. The endodevice has an intervention tool arranged to manipulate a target tissue inside the human or animal body. The intervention tool is arranged at the distal end of the liaising structure. The endodevice further includes a positioning unit having a moving formation arranged to dislocate the intervention tool relative to the target tissue, and an anchoring formation arranged to fix the moving formation to a fixing tissue inside the human or animal body such that the target tissue is positioned in a workspace of the intervention tool.Type: GrantFiled: June 25, 2018Date of Patent: April 4, 2023Assignee: UNIVERSITÄT BASELInventors: Manuela Eugster, Patrick Weber, Georg Rauter
-
Publication number: 20230099822Abstract: The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.Type: ApplicationFiled: January 18, 2021Publication date: March 30, 2023Applicant: UNIVERSITÄT BASELInventors: Gennaro DE LIBERO, Lucia MORI, Alessandro VACCHINI, Andrew CHANCELLOR, Julian SPAGNUOLO, Qinmei YANG
-
Patent number: 11499168Abstract: The invention relates to a method to determine a homology directed repair (HDR) event within a eukaryotic cell, wherein the cell expresses a first isoform of a surface protein, which is different from a second isoform of said surface protein with regard to an amino acid marker. The method comprises the steps of inducing a DNA double strand break, providing a HDR template DNA construct comprising the amino acid marker corresponding to the second isoform of the surface protein and subsequently determining the expression of the first or second isoform of said surface protein on said cell, wherein expression of the second isoform indicates a successful HDR event. The invention also relates to a method for editing a genomic location of interest within a eukaryotic cell, and to a method of selectively depleting or enriching an edited cell in a composition of non-edited and edited cells.Type: GrantFiled: April 25, 2017Date of Patent: November 15, 2022Assignee: UNIVERSITAT BASELInventors: Mara Kornete, Lukas Jeker
-
Patent number: 11484572Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.Type: GrantFiled: August 4, 2017Date of Patent: November 1, 2022Assignees: UNIVERSITÄT BASEL, UNIVERSITÄT ZURICHInventors: Osiris Marroquin Belaunzaran, Christoph Renner, Ulf Petrausch
-
Publication number: 20220339250Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.Type: ApplicationFiled: June 26, 2022Publication date: October 27, 2022Applicants: UNIVERSITAT ZURICH, UNIVERSITAT BASELInventors: Osiris MARROQUIN BELAUNZARAN, Ulf PETRAUSCH, Christoph RENNER
-
Publication number: 20220339271Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.Type: ApplicationFiled: September 11, 2019Publication date: October 27, 2022Applicant: Universität BaselInventors: Gennaro DE LIBERO, Marco LEPORE, Lucia MORI